The overall goal of this project is to define mechanisms involved in the antitumor activity of human recombinant IL-1 in RIF-1 and Panc02 murine tumor models, and to investigate new approaches to solid tumor therapy by combining IL-1 and chemotherapy. Clonogenic cell survival and regrowth delay endpoints will be used to determine dose and time dependent IL-1 mediated tumor cytotoxicity. Since IL-1 is not cytotoxic to RIF-1 cells, in continuous culture, in vivo cytotoxicity is likely mediated by tumor host cells. This hypothesis will be tested in studies to define the role of tumor macrophages and their products (e.g. TNF) in IL-1 mediated tumor cell kill in vivo. IL-1 mediated vascular and proliferative responses could influence the effectiveness of other therapeutic modalities in solid tumors. Time and dose response studies will be conducted to determine the effects of IL-1 on blood flow, vascular patency tumor pH and water distribution in tumor and normal tissues by isotope dilution methods. The regulatory role of adrenal hormones and prostaglandins, in IL-1 mediated vascular responses, and the importance of reduced tumor blood flow and tumor pH, in IL-1 mediated cytotoxicity, will be studied. Since IL-1 might be used with other modalities, the effect of immunosuppressive therapy (chemotherapy, surgery) on IL-1 antitumor activity will be determined. The information from these experiments will be used to design therapeutic strategies in which chemotherapy (Cp, Adr, liposome encapsulated Adr) is applied to exploit IL-1 mediated antitumor activities. These strategies will be tested in RIF-1 and Panc02 tumors, using clonogenic cell survival and regrowth delay endpoints. The results from these studies will provide the conceptual framework for the use of IL-1, as a single agent and in combination with chemotherapy and surgery, to improve the management of human malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA049143-02
Application #
3193116
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1989-09-01
Project End
1992-08-31
Budget Start
1990-09-01
Budget End
1991-08-31
Support Year
2
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
Miami
State
FL
Country
United States
Zip Code
33146
Braunschweiger, P G; Basrur, V S; Cameron, D et al. (1997) Modulation of cisPlatin cytotoxicity by interleukin-1 alpha and resident tumor macrophages. Biotherapy 10:129-37
Braunschweiger, P G; Basrur, V; Santos, O et al. (1996) Radioresistance in murine solid tumors induced by interleukin-1. Radiat Res 145:150-6
Braunschweiger, P G; Basrur, V S; Santos, O et al. (1993) Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors. Cancer Res 53:1091-7
Braunschweiger, P G; Jones, S A; Johnson, C S et al. (1991) Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents. Int J Radiat Biol 60:369-72
Braunschweiger, P G; Jones, S A; Johnson, C S et al. (1991) Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Cancer Res 51:5454-60
Braunschweiger, P G; Kumar, N; Constantinidis, I et al. (1990) Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole. Cancer Res 50:4709-17